Under construction – not a live service
Sign in
Not yet taking people in FranceNo phase

Studies brain changes after stroke in patients with arm weakness

Follows brain changes with functional MRI in adults with upper limb weakness after stroke.

Plain-language title generated from the registry record
Registry title: Stroke Cerebral Reorganization Pathways (SPECTRE)

Key facts

Where
Rennes, FranceSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT06784518, who can take part

Where in France

  • Rennes - CHURennes, FranceNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Rennes University Hospital
Trial code
NCT06784518
Record updated
2 April 2026
Original description
SPECTRE is a prospective longitudinal study in order to identify whether patients with different degrees of motor recovery are distinguished by distinct brain post-stroke plasticity patterns in the acute and sub-acute phases. This study allows close longitudinal follow-up of patients with severe clinical motor impairment using functional MRI to study cerebral neuroplasticity after ischemic stroke in the acute and sub-acute phase in patients with upper limb motor impairement, taking into account prognostic criteria used in current practice.Read full original descriptionShow less

Stroke Cerebral Reorganization Pathways Longitudinal Study After Stroke of the Clinical Motor Pattern and the Cerebral Reorganization According to the Different Damaged Motor Pathways (Main and Accessory) (SPECTRE)

SPECTRE is a prospective longitudinal study in order to identify whether patients with different degrees of motor recovery are distinguished by distinct brain post-stroke plasticity patterns in the acute and sub-acute phases. This study allows close longitudinal follow-up of patients with severe clinical motor impairment using functional MRI to study cerebral neuroplasticity after ischemic stroke in the acute and sub-acute phase in patients with upper limb motor impairement, taking into account prognostic criteria used in current practice.

Inclusion: Adult (age greater than or equal to 18 years) less than 75 years of age, both sexes; single supratentorial ischemic stroke confirmed by brain imaging; Upper limb deficit defined by a SAFE score <5 (SAFE Stinear protocol, prognosis of post-stroke upper limb recovery) on D3 of stroke. This corresponds to the sum of shoulder abduction and finger extension according to the MRC (Medical Research Council) scale for each of these movements out of 5; Absence of comprehension disorders limiting participation; Patient covered by french social security; Free, informed and written consent signed by the patient or a member of the patient's family (in the case of a patient who is able to understand the information and give consent but has motor difficulties resulting in an invalid signature); Non-Inclusion Criteria:; Multiple ischemic strokes or history of clinically significant stroke ; Posterior fossa stroke ; Hemorrhagic stroke; Patient who have undergone thrombolysis or mechanical thrombectomy; Extensive Fazekas grade 3 vascular leukopathy; Pre-existing neurodegenerative pathology; Patient with severe dyspnea or swallowing disorders who cannot undergo brain MRI; Adults under legal protection (safeguard of justice, curatorship, guardianship, family habilitation), persons deprived of liberty; Women declaring that they are pregnant or breast-feeding; Patient participating in another therapeutic or drug intervention study that may have an impact on the effect of cerebral neuroplasticity on the SPECTRE study; Patients with contraindications to MRI pacemaker or implantable defibrillator, neurosurgical clips, cochlear implants, intra-orbital or encephalic metallic foreign bodies, stents placed less than 4 weeks ago and osteosynthesis devices placed less than 6 weeks ago, claustrophobia.

Exclusion: Recurrence of clinically significant stroke (with worsening NIHSS score > 4) during study; If the prognostic group according to the PREP2 algorithm (good, limited and poor) has already been reached during motor evoked potential assessment the patient is excluded.

ClinicalTrials.gov NCT06784518